Stockscreener 앱 받기
4.39
0.79%
-0.035
시장 영업 전:
4.39
전일 마감가:
$4.425
열려 있는:
$4.405
하루 거래량:
1.22M
Relative Volume:
0.24
시가총액:
$1.05B
수익:
$251.85M
순이익/손실:
$-72.58M
주가수익비율:
-14.01
EPS:
-0.3134
순현금흐름:
$-63.80M
1주 성능:
-4.57%
1개월 성능:
+20.94%
6개월 성능:
-20.33%
1년 성능:
-22.85%
1일 변동 폭
$4.34
$4.41
1주일 범위
$4.32
$4.69
52주 변동 폭
$3.21
$7.18
Ardelyx Inc Stock (ARDX) Company Profile
명칭
Ardelyx Inc
전화
510-745-7047
주소
34175 ARDENWOOD BLVD., FREMONT, CA
ARDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.39 | 1.06B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-18 | 재개 | H.C. Wainwright | Buy |
| 2025-05-02 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | 재개 | Ladenburg Thalmann | Buy |
| 2025-03-04 | 개시 | BTIG Research | Buy |
| 2024-11-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-18 | 개시 | Raymond James | Strong Buy |
| 2023-09-07 | 개시 | H.C. Wainwright | Buy |
| 2023-08-25 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-11-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-07-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-23 | 개시 | Wedbush | Outperform |
| 2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-20 | 재개 | Citigroup | Buy |
| 2020-02-18 | 재개 | Jefferies | Buy |
| 2020-02-12 | 개시 | Citigroup | Buy |
| 2020-02-10 | 개시 | Cowen | Outperform |
| 2019-04-08 | 개시 | Piper Jaffray | Overweight |
| 2018-08-24 | 개시 | Jefferies | Buy |
| 2018-03-19 | 재개 | Leerink Partners | Outperform |
| 2017-11-29 | 재확인 | Citigroup | Buy |
| 2017-11-22 | 재확인 | Ladenburg Thalmann | Buy |
| 2017-10-17 | 재개 | Leerink Partners | Outperform |
| 2016-03-31 | 개시 | Ladenburg Thalmann | Buy |
| 2016-03-09 | 개시 | Cantor Fitzgerald | Buy |
| 2016-03-03 | 개시 | Citigroup | Buy |
모두보기
Ardelyx Inc 주식(ARDX)의 최신 뉴스
Ardelyx (ARDX) Announced New data for IBSRELA - MSN
What drives Ardelyx Inc. stock priceUnstoppable profit momentum - Autocar Professional
Is Ardelyx Inc. a good long term investmentConsistent triple returns - jammulinksnews.com
What analysts say about Ardelyx Inc. stockFree Capital Allocation Plans - jammulinksnews.com
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
5 stocks with growth potential: SOUN, JBL, MNTN, ARDX, RCEL - Markets.com
Ardelyx Announces Q2 2025 Financial Results Conference Call - AInvest
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025 - The Globe and Mail
Ardelyx Inc. Stock Analysis and ForecastAccelerated wealth expansion - Autocar Professional
Lobbying Update: $540,000 of ARDELYX INC. lobbying was just disclosed - Nasdaq
Wedbush Issues Negative Outlook for Ardelyx Earnings - MarketBeat
This Small-Cap Stock Could 10x By 2030, But It’s Not For The Faint Of Heart - Barchart.com
Wedbush Raises Price Target on Ardelyx to $13 From $11, Keeps Outperform Rating - MarketScreener
Long Term Trading Analysis for (ARDX) - news.stocktradersdaily.com
Jefferies Maintains a Buy Rating on Ardelyx (ARDX) With an $8 Price Target - MSN
Lobbying Update: $50,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues Despite A 26% Share Price Rise - simplywall.st
Ardelyx Faces An Uphill Battle Despite Oral Arguments Set In XPHOZAH Appeal (NASDAQ:ARDX) - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on Ardelyx stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Ardelyx stock By Investing.com - Investing.com Nigeria
Ardelyx (ARDX) Appoints New Chief Business and HR Officers - MSN
Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT - MSN
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 – ARDX - ACCESS Newswire
Ardelyx amends loan agreement to draw $50 million and secures future options - Investing.com
Ardelyx spike attributed to Xphozah legal update - MSN
Ardelyx stock spike attributed to Xphozah update (ARDX:NASDAQ) - Seeking Alpha
(ARDX) Trading Signals - news.stocktradersdaily.com
A biopharma bolsters patient centricity and trial diversity goals through newly created role - Yahoo Finance
10 Best Healthcare Penny Stocks to Buy According to Analysts - Insider Monkey
Two Beaten-Down Biotech Stocks See Big Insider Buys - Barron's
H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy - MSN
Ardelyx Inc (ARDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.91%
0.25%
자본화:
|
볼륨(24시간):